Skip to content

Insulin-based Strategies to Prevent Hypoglycemia During Exercise

Reduction of Basal Insulin to Prevent Hypoglycemia During Exercise in Adults and Adolescents With Type 1 Diabetes Using Insulin Pump Therapy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03349489
Enrollment
20
Registered
2017-11-21
Start date
2018-05-18
Completion date
2019-01-31
Last updated
2018-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes Mellitus

Keywords

Type 1 diabetes, Exercise, Hypoglycemia, Insulin pump

Brief summary

It has been reported that insulin basal rate reduction initiated at exercise onset can reduce the hypoglycemic risk during exercise. However, another potentially more efficient strategy to prevent exercise-induced hypoglycemia could be to reduce insulin basal rate a certain time prior to exercise. The objective of this study will be to compare the efficacy of two strategies to prevent exercise-induced hypoglycemia during a 60-minute exercise at moderate intensity: 1) reduce insulin basal rate 40 minutes prior to exercise; 2) reduce insulin basal rate 90 minutes prior to exercise.

Interventions

Participants will be admitted at the research center at 14:00. At 14:30, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.

Participants will be admitted at the research center at 14:00. At 15:20, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.

The Dexcom G4 Platinum will be used to measure continuous glucose levels.

DRUGInsulin

Participant's usual fast-acting insulin analog will be used.

DEVICEInsulin pump

Participant's insulin pump will be used to infuse insulin.

Sponsors

Institut de Recherches Cliniques de Montreal
CollaboratorOTHER
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Males and females ≥ 14 years of old. 2. Clinical diagnosis of type 1 diabetes for at least two years. 3. The subject will have been on insulin pump therapy for at least 3 months. 4. Last (less than 2 months) HbA1c ≤ 10%.

Exclusion criteria

1. Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy or severe proliferative retinopathy as judged by the investigator. 2. Recent (\< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. 3. Abnormal blood panel and/or anemia. 4. Ongoing pregnancy. 5. Severe hypoglycemic episode within two weeks of screening. 6. Other serious medical illness likely to interfere with study participation or with the ability to complete the exercise periods by the judgment of the investigator (e.g. orthopedic limitation). 7. Failure to comply with team's recommendations (e.g. not willing to change pump parameters, etc.).

Design outcomes

Primary

MeasureTime frameDescription
Decrease in glucose levels60 minutes (exercise period)Difference between glucose levels at the beginning of the exercise and the lowest glucose levels from the start of the exercise until the end of exercise

Secondary

MeasureTime frame
Percentage of time of glucose levels spent between 4 and 10 mmol/L4 hours following end of exercise
Percentage of time of glucose levels spent < 4 mmol/L4 hours following end of exercise
Percentage of time of glucose levels spent below 4 mmol/L60 minutes (exercise period)
Decremental area under the curve of glucose levels60 minutes (exercise period)
Area under the curve of glucose levels < 4 mmol/L60 minutes (exercise period)
Number of patients with an exercise-induced hypoglycemia < 3.9 mmol/L60 minutes (exercise period)
Number of patients with an exercise-induced hypoglycemia < 3.5 mmol/L60 minutes (exercise period)
Number of patients requiring an oral treatment for hypoglycemia60 minutes (exercise period)
Total number of hypoglycemia episodes requiring treatment60 minutes (exercise period)
Percentage of time of glucose levels spent > 10 mmol/L60 minutes (exercise period)
Percentage of time of glucose levels spent between 4-10 mmol/L60 minutes (exercise period)
Mean time (minutes) to the first hypoglycemic event60 minutes (exercise period)
Amount of carbohydrates needed to treat a hypoglycemic event60 minutes (exercise period)
Muscle blood flow60 minutes (exercise period)
Total amount of carbohydrates needed to treat hypoglycemic events4 hours following end of exercise

Countries

Canada

Contacts

Primary ContactSemah Tagougui
semah.tagougui@ircm.qc.ca514-987-5500
Backup ContactVirginie Messier
virginie.messier@ircm.qc.ca514-987-5500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026